Nan Fajun
fjnan@mail.shcnc.ac.cn
Chinese, English
Shanghai
University of Chinese Academy of Sciences
Medical School
  • 1994-09 to 1997-06 PhD: Shanghai Institute of Organic Chemistry
  • 1991-09 to 1994-06 Master's: Lanzhou University
  • 1987-09 to 1991-06 Bachelor's: Lanzhou University
  • 2000-05 to 2016-06 - Shanghai Institute of Materia Medica - Researcher
  • 1997-08 to 2000-05 - Georgetown University Medical Center - Postdoctoral
  • 2014-08-31 to 2016-06-17 - East China Normal University - Adjunct Professor
  • 2011-05-01 to 2016-06-17 - Shanghai Pharmaceutical Association - Director
  • 2005-07-01 to 2016-06-17 - Drug Discovery Today - Advisory Editorial Board
  • 2004-09-01 to 2016-06-17 - Huazhong University of Science and Technology - Adjunct Professor
  • Pudong New Area Science and Technology Progress Award (2015): First Prize
  • First Batch of Leading Talents in Scientific and Technological Innovation of the 'Ten Thousand Talents Program' (2013): National Level
  • National 'New Century Talents Project' (2009): National Level
  • Shanghai Leading Talent Award (2007): Provincial Level
  • Shanghai Science and Education Party Committee System Youth Science and Technology Innovation Talent Award (2006): Provincial Level
  • 8th Wu Jieping Medical Research Award - Paul Janssen Pharmaceutical Research (2004): Second Prize
  • Establishment of National New Drug Screening Center and Research and Application of High-Throughput Screening Technology (2003): Second Prize, National Level
  • Research and Application of Modern New Drug Screening System and High-Throughput Screening Technology (2002): First Prize, Provincial Level
Drug Synthesis Chemistry
  • Effect of a hepatitis B virus inhibitor, NZ-4, on capsid formation, 11th Author, 2016
  • Design and synthesis of simple, yet potent and selective non-ring-A pyripyropene A-based inhibitors of acyl-coenzyme A: cholesterol acyltransferase 2 (ACAT2), 5th Author, 2016
  • Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy, 11th Author, 2016
  • Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel, 8th Author, 2015
  • P-Retigabine: An N-Propargyled Retigabine with Improved Brain Distribution and Enhanced Antiepileptic Activity, 10th Author, 2015
  • Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth, 13th Author, 2015
  • Targeting the gamma-/beta-secretase interaction reduces beta-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis, 11th Author, 2015
  • Potent and Orally Efficacious Bisthiazole-Based HistoneDeacetylase Inhibitors, 7th Author, 2014
  • Design and synthesis of 3,3 '-biscoumarin-based c-Met inhibitors, 7th Author, 2014
  • Highly lipophilic 3-epi-betulinic acid derivatives as potent and selective TGR5 agonists with improved cellular efficacy, 6th Author, 2014
  • Total Synthesis of Aphadilactones A-D, 4th Author, 2014
  • Single-Cell Chemical Proteomics with an Activity-Based Probe: Identification of Low-Copy Membrane Proteins on Primary Neurons, 11th Author, 2014
  • Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors, 8th Author, 2014
  • Discovery of a NegativeAllosteric Modulator of GABA B Receptors, 7th Author, 2014
  • Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation, 11th Author, 2014
  • Small molecule compound induces chromatin de-condensation and facilitates induced pluripotent stem cell generation, 9th Author, 2014
Drug Synthesis Organic Chemistry Pharmaceutical Chemistry Chemical Synthesis Medicinal Chemistry Drug Development Synthetic Methods Chemical Reactions Molecular Design Bioorganic Chemistry

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.